Novel drug target may help overcome resistance to EZH2 inhib

Inhibitors of the protein EZH2 are effective against cancers with SMARCB1 mutations such as rhabdoid tumors in children.

Related Keywords

Yiannis Drosos , Taosheng Chen , Emma Beane , Margaret Larsen , Emily Henderson , Santhosh Upadhyaya , Natarajan Bhanu , Charles Wm Roberts , Sandi Radko Juettner , Jacquelyn Myers , Baranda Hansen , Sandeep Dhanda , Robert Mobley , Janet Partridge , Xiaotu Ma , Benjamin Garcia , Samuel Peters , Shondra Pruett Miller , Kaeli Mathias , Broad Institute , Jude Oncology Department , National Cancer Institute , Jude Children Research Hospital , Garretb Smith Foundation , Drug Administration , Jude Comprehensive Cancer Center , University Of Pennsylvania , Jude Children , Research Hospital , Jude Comprehensive Cancer , Jude Oncology , Jude Collaborative Research Consortium , Chromatin Regulation , Federica Piccioni , David Root , Jonathan Low , Cancer , Rain , Fell , Children , Chromatin , Drugs , Wood , Gene , Ene Expression , Genes , Hospital , Alignant , Utation , Mh , Protein , Research , Humor ,